Thromb Haemost 1989; 62(03): 955-961
DOI: 10.1055/s-0038-1651035
Original Article
Schattauer GmbH Stuttgart

Differential Ability of Agonists to Express Distinct Pools of Fibrinogen (Gpllb/llla) Receptors which Can Mediate the Aggregation of Human Platelets

Ian S Watts
The Department of Cardiovascular Pharmacology, Glaxo Group Research Ltd, Ware, Hertfordshire, UK
,
Rebecca J Keery
The Department of Cardiovascular Pharmacology, Glaxo Group Research Ltd, Ware, Hertfordshire, UK
,
Philip Lumley
The Department of Cardiovascular Pharmacology, Glaxo Group Research Ltd, Ware, Hertfordshire, UK
› Author Affiliations
Further Information

Publication History

Received: 25 January 1989

Accepted after revision 29 May 1989

Publication Date:
30 June 2018 (online)

Summary

We have investigated the effect of two procedures that modify human platelet surface membrane glycoprotein (Gp) IIb and IIIa complexes upon whole blood platelet aggregation to a range of agonists. (A) Irreversible disruption of complexes by temporary (30 min) Ca2+-deprivation with EGTA at 37° C. (B) Binding of a monoclonal antibody M148 to the complex. EGTA exposure abolished aggregation to ADP, adrenaline and PAF. In contrast, full aggregation curves to collagen and U-46619 could still be established. EGTA exposure reduced M148 binding to platelets by 80%. Excess M148 abolished aggregation to ADP, PAF, collagen and U-46619. However, upon removal of unbound antibody from platelets full aggregation curves to collagen and U-46619 but not to ADP and PAF could be re-established. Thus human platelet aggregation to ADP, PAF and adrenaline appears absolutely dependent upon surface membrane GpIIb/IIIa complexes. In contrast, collagen and U-46619 cause expression of an additional distinct pool of Gp complexes inaccessible to EGTA and M148 in unstimulated platelets which is intimately involved in aggregation to these agonists.

 
  • References

  • 1 Zucker MB, Grant RA. Nonreversible loss of platelet aggregability induced by calcium deprivation. Blood 1978; 52: 505-514
  • 2 Nachman RL, Leung LL K. Complex formation of platelet membrane glycoproteins IIb and IIIa with fibrinogen. J Clin Invest 1982; 69: 263-269
  • 3 Gogstad GO, Brosstad F, Krutnes MB, Hagen I, Solum NO. Fibrinogen-binding properties of the human platelet glycoprotein IIb-IIIa complex: A study using crossed radioimmunoelectrophoresis. Blood 1982; 60: 663-671
  • 4 Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 1979; 64: 1393-1401
  • 5 Kunicki TJ, Pidard D, Rosa JP, Nurden AT. The formation of Ca2+-dependent complexes of platelet membrane glycoproteins IIb and IIIa in solution as determined by crossed immunoelectrophoresis. Blood 1981; 58: 268-278
  • 6 Jennings LK, Phillips DR. Purification of glycoproteins IIb and III from human platelet plasma membranes and characterisation of a calcium-dependent glycoprotein IIb-III complex. J Biol Chem 1982; 257: 10458-10466
  • 7 Fujimura K, Phillips DR. Calcium cation regulation of glycoprotein IIb-IIIa complex formation in platelet plasma membranes. J Biol Chem 1983; 258: 10247-10252
  • 8 Shattil SJ, Brass LF, Bennett JS, Pandhi P. Biochemical and functional consequences of dissociation of the platelet membrane glycoprotein IIb-IIIa complex. Blood 1985; 66: 92-98
  • 9 Lumley P, Humphrey PP A. A method for quantitating platelet aggregation and analyzing drug-receptor interactions on platelets in whole blood in vitro. J Pharmacol Methods 1981; 6: 153-166
  • 10 Keery RJ, Lumley P. AH6809, a prostaglandin DP-receptor blocking drug on human platelets. Br J Pharmacol 1988; 94: 745-754
  • 11 Lumley P, White BP, Humphrey PP A. GR32191, a highly potent and specific thromboxane A2-receptor blocking drug on platelets and vascular and airways smooth muscle in vitro. Br J Pharmacol 1989; 97: 783-794
  • 12 Jones D, Fritschy J, Garson J, Nokes TJ C, Kemshead JT, Hardisty RM. A monoclonal antibody binding to human medulloblastoma cells and to the platelet glycoprotein IIb-IIIa complex. Br J Haematol 1984; 57: 621-631
  • 13 Pidard D, Didry D, Kunicki TJ, Nurden AT. Temperature-dependent effects of EDTA on the membrane glycoprotein IIb-IIIa complex and platelet aggregability. Blood 1986; 67: 604-611
  • 14 Brass LF, Shattil SJ, Kunicki TJ, Bennett JS. Effect of calcium on the platelet membrane glycoprotein IIb-IIIa complex. J Biol Chem 1985; 260: 7875-7881
  • 15 Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-338
  • 16 Woods VL, Wolff LE, Keller DM. Resting platelets contain a substantial centrally located pool of glycoprotein IIb-IIIa complex which may be accessible to some but not other extracellular proteins. J Biol Chem 1986; 261: 15242-15251
  • 17 Gogstad GO, Hagen I, Korsmo R, Solum NO. Characterisation of the proteins of isolated human platelet a granules. Evidence for a separate a granule pool of the glycoproteins IIb and IIIa. Biochim Biophys Acta 1981; 670: 150-162
  • 18 Wencel-Drake JD, Plow EF, Kunicki TJ, Woods VL, Keller DM, Ginsberg M. Localization of internal pools of membrane glycoproteins involved in platelet adhesive responses. Am J Pathol 1986; 124: 324-334
  • 19 Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein IIb/IIIa complex during platelet activation. J Biol Chem 1985; 260: 11107-11114
  • 20 McEver RP, Martin MN. A monoclonal antibody to a membrane glycoprotein binds only to activated platelets. J Biol Chem 1984; 259: 9799-9804
  • 21 DiMinno G, Silver MJ, Cerbone AM, Riccardi G, Rivellese A, Mancini M, Thiagarajan P. Increased binding of fibrinogen to platelets in diabetes: the role of prostaglandins and thromboxane. Blood 1985; 65: 156-162
  • 22 Niiya K, Hodson E, Bader R, Byers-Ward V, Koziol JA, Plow EF, Ruggeri ZM. Increased expression of the membrane glycoprotein IIb/ IIIa complex induced by platelet activation. Relationship to the binding of fibrinogen and platelet aggregation. Blood 1987; 70: 475-483
  • 23 Coller BS, Scudder LE, Berger HJ, Iuliucci JD. Inhibition of human platelet function in vivo with a monoclonal antibody. Ann Intern Med 1988; 109: 635-638